Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001923502 | SCV002192925 | uncertain significance | Naxos disease; Arrhythmogenic right ventricular dysplasia 12 | 2021-03-07 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs202091411, ExAC 0.002%). This variant has not been reported in the literature in individuals with JUP-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces methionine with isoleucine at codon 76 of the JUP protein (p.Met76Ile). The methionine residue is weakly conserved and there is a small physicochemical difference between methionine and isoleucine. |
Fulgent Genetics, |
RCV001923502 | SCV002792942 | uncertain significance | Naxos disease; Arrhythmogenic right ventricular dysplasia 12 | 2021-08-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004043556 | SCV003983645 | uncertain significance | Cardiovascular phenotype | 2023-05-30 | criteria provided, single submitter | clinical testing | The c.228G>A (p.M76I) alteration is located in exon 3 (coding exon 2) of the JUP gene. This alteration results from a G to A substitution at nucleotide position 228, causing the methionine (M) at amino acid position 76 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |